Brian D VanScoy (B D VanScoy, Brian VanScoy)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 16

Top Topics

Escherichia Coli

Urinary Tract Infection

Molecularly Imprinted

Patient Satisfaction

Top Venues

Antimicrobial agents and chemotherapy

This page only lists publications with an associated author ORCID identifier.

Publications

Alexander J Lepak, Brian D VanScoy, Christopher M Rubino, Paul G Ambrose, David R Andes
In vivo pharmacodynamic characterization of a next-generation polyene, SF001, in the invasive pulmonary aspergillosis mouse model. Antimicrobial agents and chemotherapy 68 (3) (2024)
Alexander J Lepak, Brian D VanScoy, Christopher M Rubino, Paul G Ambrose, David R Andes
In vivo pharmacodynamic characterization of a next-generation polyene, SF001, in the invasive pulmonary aspergillosis mouse model. Antimicrobial agents and chemotherapy (2024)
Alexander J Lepak, Brian D VanScoy, Christopher M Rubino, Paul G Ambrose, David R Andes
In vivo pharmacodynamic characterization of a next-generation polyene, SF001, in the invasive pulmonary aspergillosis mouse model. Antimicrobial agents and chemotherapy 68 (3) (2024)
Alexander J Lepak, Brian D VanScoy, Christopher M Rubino, Paul G Ambrose, David R Andes
In vivo pharmacodynamic characterization of a next-generation polyene, SF001, in the invasive pulmonary aspergillosis mouse model. Antimicrobial agents and chemotherapy 68 (3) (2024)
Alexander J Lepak, Brian D VanScoy, Christopher M Rubino, Paul G Ambrose, David R Andes
In vivo pharmacodynamic characterization of a next-generation polyene, SF001, in the invasive pulmonary aspergillosis mouse model. Antimicrobial agents and chemotherapy 68 (3) (2024)
Alexander J Lepak, Brian D VanScoy, Christopher M Rubino, Paul G Ambrose, David R Andes
In vivo pharmacodynamic characterization of a next-generation polyene, SF001, in the invasive pulmonary aspergillosis mouse model. Antimicrobial agents and chemotherapy 68 (3) (2024)
Brian D VanScoy, S Jones, H Conde, L V Friedrich, Nicole Cotroneo, Sujata M Bhavnani, Paul G Ambrose
Evaluation of Oral Tebipenem as a Step-Down Therapy following Intravenous Ertapenem against Extended-Spectrum β-Lactamase-Producing Escherichia coli in a Hollow-Fiber In Vitro Infection Model. Antimicrobial agents and chemotherapy 67 (3) (2023)
Brian D VanScoy, S Jones, H Conde, L V Friedrich, Nicole Cotroneo, Sujata M Bhavnani, Paul G Ambrose
Evaluation of Oral Tebipenem as a Step-Down Therapy following Intravenous Ertapenem against Extended-Spectrum β-Lactamase-Producing Escherichia coli in a Hollow-Fiber In Vitro Infection Model. Antimicrobial agents and chemotherapy 67 (3) (2023)
Brian D VanScoy, S Jones, H Conde, L V Friedrich, Nicole Cotroneo, Sujata M Bhavnani, Paul G Ambrose
Evaluation of Oral Tebipenem as a Step-Down Therapy following Intravenous Ertapenem against Extended-Spectrum β-Lactamase-Producing Escherichia coli in a Hollow-Fiber In Vitro Infection Model. Antimicrobial agents and chemotherapy 67 (3) (2023)
A J Lepak, Michael Trang, J P Hammel, Helio Silva Sader, Sujata M Bhavnani, Brian D VanScoy, J M Pogue, Paul G Ambrose, David R Andes, null null
Development of Modernized Acinetobacter baumannii Susceptibility Test Interpretive Criteria for Recommended Antimicrobial Agents Using Pharmacometric Approaches. Antimicrobial agents and chemotherapy (2023)
Brian D VanScoy, S Jones, H Conde, L V Friedrich, Nicole Cotroneo, Sujata M Bhavnani, Paul G Ambrose
Evaluation of Oral Tebipenem as a Step-Down Therapy following Intravenous Ertapenem against Extended-Spectrum β-Lactamase-Producing Escherichia coli in a Hollow-Fiber In Vitro Infection Model. Antimicrobial agents and chemotherapy (2023)
Brian D VanScoy, S Jones, H Conde, L V Friedrich, Nicole Cotroneo, Sujata M Bhavnani, Paul G Ambrose
Evaluation of Oral Tebipenem as a Step-Down Therapy following Intravenous Ertapenem against Extended-Spectrum β-Lactamase-Producing Escherichia coli in a Hollow-Fiber In Vitro Infection Model. Antimicrobial agents and chemotherapy 67 (3) (2023)
Sujata M Bhavnani, Jeffrey P Hammel, Elizabeth A Lakota, Michael Trang, Justin C Bader, Catharine C Bulik, Brian D VanScoy, Christopher M Rubino, Michael D Huband, Lawrence Friedrich, Judith N Steenbergen, Paul G Ambrose
Pharmacokinetic-Pharmacodynamic Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients with Community-Acquired Bacterial Pneumonia Arising from Streptococcus pneumoniae and Haemophilus influenzae. Antimicrobial agents and chemotherapy (2023)
Brian D VanScoy, Elizabeth A Lakota, Haley Conde, Steven Fikes, Sujata M Bhavnani, Philippa B Elefante, Nicole E Scangarella-Oman, Paul G Ambrose
Gepotidacin Pharmacokinetics-Pharmacodynamics against Escherichia coli in the One-Compartment and Hollow-Fiber In Vitro Infection Model Systems. Antimicrobial agents and chemotherapy 65 (12) (2021)
Sujata M Bhavnani, Jeffrey P Hammel, Elizabeth A Lakota, M Courtney Safir, Brian D VanScoy, Yu Nagira, Christopher M Rubino, Nobuo Sato, Tomokazu Koresawa, Kenichiro Kondo, Paul G Ambrose
Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Support Dose Selection for ME1100, an Arbekacin Inhalation Solution. Antimicrobial agents and chemotherapy 64 (10) (2020)
Brian D VanScoy, Nicole E Scangarella-Oman, Steven Fikes, Sharon Min, Jianzhong Huang, Karen Ingraham, Sujata M Bhavnani, Haley Conde, Paul G Ambrose
Relationship between Gepotidacin Exposure and Prevention of On-Therapy Resistance Amplification in a Neisseria gonorrhoeae Hollow-Fiber In Vitro Infection Model. Antimicrobial agents and chemotherapy 64 (10) (2020)